Technical Analysis for CALA - Calithera Biosciences, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| See historical CALA trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| MACD Bearish Centerline Cross | Bearish | 0.00% | |
| MACD Bearish Signal Line Cross | Bearish | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| 20 DMA Resistance | Bearish | -3.02% | |
| NR7 | Range Contraction | -3.02% | |
| Down 3 Days in a Row | Weakness | -3.02% | |
| Down 4 Days in a Row | Weakness | -3.02% | |
| Down 5 Days in a Row | Weakness | -3.02% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/08/2019
- Sector: Healthcare
- Industry: Biotechnology
Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Its lead product candidate includes CB-839, an inhibitor of glutaminase, which is in three Phase I clinical trials for the treatment of patients with solid tumors, leukemias, lymphomas, and multiple myeloma. The company was founded in 2010 and is headquartered in South San Francisco, California.
Medicine Biopharmaceutical Cancer Treatment Of Cancer Oncology Solid Tumors Tumor Lymphoma Multiple Myeloma Targeted Therapy Anatomical Pathology Hematology Lymphomas Phosphoinositide 3 Kinase Inhibitor Leukemias
Medicine Biopharmaceutical Cancer Treatment Of Cancer Oncology Solid Tumors Tumor Lymphoma Multiple Myeloma Targeted Therapy Anatomical Pathology Hematology Lymphomas Phosphoinositide 3 Kinase Inhibitor Leukemias
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more CALA news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 6.9 |
| 52 Week Low | 3.43 |
| Average Volume | 276,769 |
| 200-Day Moving Average | 4.9678 |
| 50-Day Moving Average | 4.0447 |
| 20-Day Moving Average | 3.9978 |
| 10-Day Moving Average | 4.108 |
| Average True Range | 0.2237 |
| ADX | 13.84 |
| +DI | 15.1674 |
| -DI | 21.403 |
| Chandelier Exit (Long, 3 ATRs ) | 3.7389 |
| Chandelier Exit (Short, 3 ATRs ) | 4.4111 |
| Upper Bollinger Band | 4.3118 |
| Lower Bollinger Band | 3.6838 |
| Percent B (%b) | 0.26 |
| BandWidth | 15.70864 |
| MACD Line | -0.0006 |
| MACD Signal Line | 0.0073 |
| MACD Histogram | -0.0079 |
| Fundamentals | Value |
|---|---|
| Market Cap | 136.58 Million |
| Num Shares | 35.5 Million |
| EPS | -1.14 |
| Price-to-Earnings (P/E) Ratio | -3.38 |
| Price-to-Sales | 47.73 |
| Price-to-Book | 3.36 |
| PEG Ratio | -0.25 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.15 | ||||
| Resistance 3 (R3) | 4.16 | 4.08 | 4.10 | ||
| Resistance 2 (R2) | 4.08 | 4.00 | 4.07 | 4.08 | |
| Resistance 1 (R1) | 3.96 | 3.95 | 3.92 | 3.95 | 4.07 |
| Pivot Point | 3.88 | 3.88 | 3.86 | 3.87 | 3.88 |
| Support 1 (S1) | 3.76 | 3.80 | 3.72 | 3.75 | 3.63 |
| Support 2 (S2) | 3.68 | 3.75 | 3.67 | 3.62 | |
| Support 3 (S3) | 3.56 | 3.68 | 3.60 | ||
| Support 4 (S4) | 3.55 |
